Toxoplasma gondii parasite is one of the world's most common parasites which is an intracellular parasite. The aim of this work is to investigate the effect of nitrofurantoin given at a dose of 100mg/kg(2mg for each mouse) , spiramycin given at a dose of 200mg/k.g (4mg for each mouse) and a combination of both(4 days post infection for 2 weeks) on the brain cyst count of infected mice (54 laboratory-bred Swiss albino mice). Mice were contaminated for 10 cysts for Toxoplasma gondii (ME 49 strain). Five aggregations for mice were utilized within those study,three bunches for them accepted medicines and the different two were ordinary Furthermore contaminated non treated aggregations. One bunch approached with spiramycin,other approached for nitrofurantoin, and the final one approached for the blending for both. The mice were sacrified then afterward 8 weeks. The blending for both pills made 4 days post spoiling for two weeks brought about critical diminishment in the mind growth check (78) with diminishment rate( 85. 2% ) contrasted with different gatherings. This goal that nitrofurantoin Might be an satisfactory antitoxoplasmic medication regardless same time its mix with spiramycin provided for those best result.

Background: Standard therapies for toxoplasmosis have serious adverse effects and can't eliminate the cyst stage of chronic infection. Highly effective medications with few adverse effects are required. This work aimed to determine the efficacy of nitrofurantoin in the treatment of chronic toxoplasmosis as a means of overwhelming the limitations of other standard medications. Methods: A total of 42 laboratory-bred Swiss female albino mice were included. Six mice were left in the non-infected, non-treated group (G 1). The rest (12mice/ each group) were experimentally infected orally with the T. gondii strain (ME49). Six weeks post-infection the experimental mice were divided into four groups.Group1:uninfected, untreated; Group2:infected, untreated mice (infected control); Group3:infected treated mice with nitrofurantoin for two weeks and Group 4: infected mice treated with a combination of nitrofurantoin and spiramycin for two weeks. Sixty days after infection, all mice were slaughtered. Parasitological (brain cyst count) and histological (using hematoxylin and eosin) measures were used to assess the therapeutic impact of nitrofurantoin in chronically infected mice (H & E). Results: High significant reduction of mean brain cyst count was observed in the nitrofurantoin monotherapy group in comparison with the infected control group. The combination-treated group had the best treatment efficacy, with the highest rates of brain cyst decrease. Histopathological studies of the brain tissues showed an obvious correlation with the results of the brain cyst counts. Conclusions: Nitrofurantoin is a possible anti-T.gondii option for clinical usage in chronic toxoplasmosis, as it enhances the antitoxoplasmic effect of standard toxoplasmosis treatment.